Q-omics provides the consensus-scored CCDC17 profile across patient tissues and cancer cell-line models. CCDC17 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CCDC17 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, CCDC17 RNA expression shows 17,452 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KICH, and UVM as cancer lineages where CCDC17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC17 survival associations across molecular data types. CCDC17 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC17 RNA expression–survival associations across cancer types. High CCDC17 expression shows unfavorable associations in ACC, KIRC and OV, but favorable associations in UCS, PAAD and UCEC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CCDC17 RNA expression.
This table summarizes CCDC17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CCDC17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC17 shows lower tumor expression in KICH, LUAD, LUSC, BRCA and THCA and higher tumor expression in LIHC. The KICH box plot shows higher CCDC17 RNA expression in normal versus tumor tissue (log2 FC = −0.556, t-test p < 0.001).
This table shows molecular features associated with CCDC17 in patient tissues and cancer cell lines. In patient samples, CCDC17 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
